Catalog No.
Product Name
Application
Product Information
Citations
-
Antiviral Agent
Onradivir monohydrate is an orally active antiviral agent that targets the influenza A virus RNA polymerase PB2 subunit, exhibiting an IC50 value of 0.562 nM. This compound effectively inhibits cap binding to the PB2 subunit, leading to suppression of viral replication, reduction of viral titers, and decreased RNA loads. In murine models, Onradivir monohydrate demonstrates improved survival rates in influenza A virus-infected mice and is a valuable tool for studying influenza A virus infections in research applications. -
Antibiotic
Alatrofloxacin is a fluoronaphthyridone antibiotic that serves as a proagent of Trovafloxacin. Its primary mechanism involves the inhibition of DNA synthesis in pathogenic organisms, resulting in effective antimicrobial activity. In addition to its antibacterial properties, Alatrofloxacin also exhibits immunosuppressive effects, making it relevant for research applications in studying immune responses and infectious diseases. -
HBV Inhibitor
HBV-IN-48 is a potent inhibitor of Hepatitis B Virus (HBV) with demonstrated antiviral activity. It effectively reduces viral replication in HepDE19 cells, achieving an EC50 value of 0.005 μM. Additionally, HBV-IN-48 has shown the ability to lower serum HBV DNA levels in mouse models, making it a valuable tool for studying HBV infections and potential therapeutic interventions. -
Antibiotic
Ficellomycin is a nitrogen-containing bicyclic antibiotic targeting Gram-positive bacteria, including multidrug-resistant Staphylococcus aureus. It exerts its biological activity by inducing the formation of defective 34S DNA fragments that disrupt the semi-conservative DNA replication process. These fragments are unable to integrate into larger DNA segments, ultimately hindering the assembly of a complete bacterial chromosome. Ficellomycin is valuable for research on bacterial diseases and antibiotic resistance mechanisms. -
DENV Inhibitor
DENV-IN-4 is a potent inhibitor of Dengue Virus (DENV), exhibiting an EC50 value of 4.79 µM in Vero cells with a selectivity index greater than 20.9. This compound effectively reduces the expression levels of DENV2 in a concentration-dependent manner and inhibits RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 is valuable for research applications focused on understanding DENV pathogenesis and developing antiviral therapies. -
HBV DNA Synthesis Inhibitor
LB80317 is an active metabolite of LB80380 that functions as a potent inhibitor of HBV DNA synthesis, exhibiting an EC50 of 0.5 μM. This compound demonstrates antiviral activity, making it a promising candidate for the treatment of chronic hepatitis B. Its ability to inhibit viral replication supports its potential utility in HBV research and therapeutic applications. -
Tetracycline derivatives of antibiotic
Sarecycline is a narrow-spectrum tetracycline derivative antibiotic that primarily targets bacterial protein synthesis by interfering with tRNA accommodation and stabilizing mRNA binding to the 70S ribosome. It exhibits significant anti-inflammatory activity and effectively inhibits the growth of Gram-positive bacteria, including various strains of keratobacterium acnes. Sarecycline is suitable for research applications focused on understanding moderate to severe acne and its underlying mechanisms. -
Antibacterial Agent
Antibacterial Agent 89 is a potent antibacterial compound that targets bacterial transcription processes. It exhibits significant anti-clostridial activity by inhibiting the release of cytotoxins and disrupting the β’CH-σ interaction. This compound is useful for research applications focused on bacterial pathogenesis and the development of novel antibacterial strategies. -
DNA Gyrase Inhibitor
DNA Gyrase-IN-11 is a selective inhibitor of DNA gyrase, targeting bacterial DNA replication and supercoiling mechanisms. It demonstrates a potent inhibitory effect on protein synthesis with an IC50 of 0.74 μM and effectively inhibits E. coli DNA gyrase with an IC50 of 11.9 μM. Additionally, DNA Gyrase-IN-11 possesses significant antibacterial activity against pathogens such as Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, with minimum inhibitory concentrations (MICs) ranging from 0.008 to 0.25 μg/mL, making it a valuable tool for antimicrobial research. -
HBV Inhibitor
HBV-IN-21 is a potent inhibitor of hepatitis B virus (HBV) DNA replication, exhibiting an IC50 of 2.2 µM. This compound demonstrates a strong interaction with the HBV core capsid protein, characterized by a dissociation constant (KD) of 60.0 μM. HBV-IN-21 is suited for research applications focused on antiviral drug development and elucidation of HBV replication mechanisms. -
DNA Synthesis/HSV/HIV-1 Inhibitor
16,16-Dimethyl prostaglandin A1 is a prostaglandin analog that primarily inhibits DNA synthesis. It demonstrates significant antiviral activity by reducing viral replication in both herpes simplex virus (HSV) and HIV-1 infection models. This compound serves as a valuable tool for research focused on cancer biology and viral pathogenesis. -
Fluoroquinolone Antibiotic
PD 124816 is an orally active fluoroquinolone antibiotic that inhibits DNA gyrase (topoisomerase IV), providing broad-spectrum antibacterial activity. It demonstrates efficacy against both Gram-positive and Gram-negative bacteria, with a minimum inhibitory concentration (MIC₉₀) of ≤ 0.06 μg/mL and an MIC₉₀ of 1 μg/mL for anaerobic bacteria such as Peptostreptococcus fragi. Additionally, PD 124816 exhibits complete bactericidal effectiveness in a mouse model of Mycobacterium leprae infection. This compound is valuable for research involving mixed infections and antibiotic resistance mechanisms. -
DENV/ZIKV Inhibitor
Antiviral agent 36 is a potent inhibitor of dengue virus (DENV) and Zika virus (ZIKV), demonstrating effective antiviral activity. It inhibits viral replication with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3. This compound serves as a valuable tool for research focused on the therapeutic development and understanding of DENV and ZIKV infections. -
Anti SARS-CoV-2 Agent
DMA-155 is an antiviral agent that targets SARS-CoV-2 by binding to 5'-terminal stem-loop RNAs, demonstrating affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b), and 48.6 μM (SL6). This compound effectively inhibits SARS-CoV-2 viral replication and significantly reduces viral RNA levels. DMA-155 is suitable for research applications related to COVID-19. -
Antitumor Antibiotic
Esperamicin A1 is a highly potent antitumor antibiotic derived from Actinomadura verrucosospora. It exhibits significant cytotoxic activity, making it valuable for cancer research applications. In addition to its antitumor properties, Esperamicin A1 functions as a click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. This allows for versatile applications in bioconjugation and molecular imaging studies. -
SARS-CoV-2 RdRp Inhibitor
RdRP-IN-10 is a selective inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), exhibiting an IC50 of 5.78 μM. This compound covalently binds to Cys114 of the SARS-CoV-2 nsp8 protein, disrupting the stabilizing interactions between nsp8 and nsp12. RdRP-IN-10 effectively inhibits RNA polymerization mediated by RdRp without interfering with the RNA-RdRp complex formation. It demonstrates antiviral activity in cellular models and serves as a valuable tool for researching SARS-CoV-2 infection mechanisms and potential therapeutic interventions. -
DENV Inhibitor
DENV-IN-7 is a flavone analog that functions as a dengue virus (DENV) inhibitor, demonstrating an EC50 value of 70 nM. This compound exhibits low toxicity to normal cells while maintaining effective antiviral activity against DENV. It is suitable for research applications focused on the development of therapeutics for dengue virus infections. -
Antibiotic
Ibezapolstat hydrochloride is a novel, orally active inhibitor of DNA polymerase IIIC (pol IIIC) with a Ki of 0.325 μM specific to the enzyme from Clostridium difficile. This compound exhibits antibiotic activity and is primarily utilized in research focused on Clostridium difficile infections (CDI). Its unique mechanism makes it a valuable tool for studying CDI and developing potential therapeutic strategies. -
Bacterial DNA Gyrase/Topo IV Inhibitor
GC-072 is a selective inhibitor of bacterial DNA gyrase and Topoisomerase IV, demonstrating potent antibacterial activity. This 4-oxoquinolizine antibiotic exhibits efficacy against a wide range of bacterial strains, including Gram-positive, Gram-negative, and multidrug-resistant organisms. Importantly, GC-072 does not interfere with human topoisomerases I and II, making it a suitable candidate for studying bacterial infections. Its bactericidal action against Burkholderia pseudomallei is significant, as it supports dose-dependent survival rates in mice during lethal inhalational models, highlighting its potential in melioidosis research. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
Bacterial DNA Gyrase B Inhibitor
DNA Gyrase-IN-3 is a specific inhibitor of bacterial DNA gyrase B, exhibiting IC50 values ranging from 5.41 to 15.64 µM against E. coli DNA gyrase. This compound demonstrates significant anti-tubercular and antibacterial activity, making it a valuable tool for microbial research. Its mechanism of action is relevant in studies aimed at developing new antibacterial agents targeting bacterial DNA replication and transcription processes. -
Bacterial Inhibitor
CI-990 (PD-131112) is a selective inhibitor of bacterial DNA gyrase, targeting key enzymes involved in DNA replication and repair. It exhibits potent antibacterial activity and is especially relevant for studying Enterococcal infections, including endocarditis and sepsis. This compound can serve as a valuable tool in microbiological research to understand bacterial resistance mechanisms and develop therapeutic strategies. -
EV71 3D Polymerase Inhibitor
DTriP-22 is a potent inhibitor of the enterovirus 71 (EV71) 3D polymerase, characterized by low toxicity. It demonstrates broad-spectrum antiviral activity against RNA viruses, particularly within the picornavirus family, while exhibiting no effects on DNA viruses. By targeting and inhibiting viral RNA synthesis during the early stages of replication, DTriP-22 serves as a valuable reagent in anti-enterovirus research applications. -
Dengue Viral Replication Inhibitor
DENV-IN-2 is a potent inhibitor of dengue viral replication, demonstrating exceptional activity against all four serotypes of the dengue virus. With an EC50 ranging from 0.013 to 0.029 nM, it shows remarkable efficacy in suppressing viral activity. This compound is valuable for research applications targeting dengue virus pathogenesis and developing antiviral strategies. -
HBV Inhibitor
HBV-IN-22 is a potent inhibitor of Hepatitis B Virus (HBV) DNA replication, demonstrating IC50 values of 0.71 μM against wild-type strains and 0.84 μM against resistant strains. This compound is valuable for research focused on antiviral drug development and understanding HBV resistance mechanisms, making it a critical tool in the study of Hepatitis B therapeutics. -
Bacterial Transcription Inhibitor
CUHK242 is a selective bacterial transcription inhibitor that effectively disrupts RNA synthesis within bacterial cells. It demonstrates a minimum inhibitory concentration (MIC) of 2 μg/mL against the B. subtilis reporter strain BS2019 and exhibits antimicrobial activity against Staphylococcus aureus. This compound is useful for research applications focused on understanding bacterial gene expression and studying the mechanisms of antibiotic resistance. -
DENV Inhibitor
DENV-IN-6 is a powerful inhibitor of dengue virus (DENV) serotypes I-IV, exhibiting effective antiviral activity with EC50 values of 17.5, 13.20, 6.8, and 11.41 μM, respectively, for the inhibition of viral replication. Additionally, DENV-IN-6 demonstrates notable activity against HIV-1 IIIB, with an EC50 of 0.0181 µM and a cytotoxicity (CC50) of 64.92 µM. This compound serves as a valuable tool for research into antiviral therapies targeting DENV and HIV-1. -
HIV Inhibitor
Fozivudine tidoxil is an orally active HIV inhibitor designed as a thioether lipid-zidovudine (ZDV) conjugate. This compound exhibits potent anti-HIV activity by incorporating into the newly synthesized DNA strand during viral replication, leading to irreversible binding to viral reverse transcriptase and disruption of the reverse transcription process. In addition to its antiviral properties, Fozivudine tidoxil is also a versatile click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with suitable alkyne or DBCO/BCN-containing molecules, making it valuable for chemical biology applications. -
HIV-1 Inhibitor
HIV-1 Inhibitor-43 is a selective inhibitor targeting the HIV-1 virus. It demonstrates potent efficacy with an EC50 of 21.3 nM for Y188L mutants, 6.2 nM for K103N-Y181C, and under 0.7 nM for both K103N and Y181C strains. This compound effectively reduces HIV-1 RNA levels and protein p24 expression, making it a valuable tool for research in HIV pathogenesis and therapeutic development. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies. -
Antibiotic
Alatrofloxacin mesylate is a broad-spectrum antibiotic that targets and inhibits bacterial growth. It demonstrates significant hydrophilicity in aqueous solutions, facilitating the formation of stable suspensions. Understanding its degradation products, which can become hydrophobic upon exposure, is essential for maintaining long-term stability, as this affects particle aggregation. Additionally, variations in surface tension characteristics under different lighting conditions can influence the physical and chemical properties of Alatrofloxacin mesylate, making it a valuable candidate for research into antibiotic efficacy and stability. -
Anti-Bacterial Agent
(Rac)-Besifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic that acts as a potent inhibitor of DNA gyrase and topoisomerase IV. This compound exhibits broad-spectrum antibacterial activity against both Gram-negative and Gram-positive aerobic and anaerobic bacteria, making it valuable in combating drug resistance. Additionally, (Rac)-Besifloxacin hydrochloride possesses anti-inflammatory properties, and it is relevant in the study of bacterial conjunctivitis. -
Bacterial DNA Gyrase B Inhibitor
DNA Gyrase-IN-2 is a potent inhibitor of bacterial DNA gyrase B, demonstrating IC50 values of 3.29-10.49 µM for Escherichia coli and 4.41-5.61 µM for Mycobacterium tuberculosis. This compound exhibits significant anti-tubercular and antibacterial activity, making it valuable for research focused on bacterial replication and antibiotic development. Its specific targeting of DNA gyrase B positions it as a promising candidate for further investigation in treating bacterial infections. -
HIV/HBV Inhibitor
L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV. -
Antibiotics
4-Demethoxy-7,9-di-epi-daunorubicin is an anthracycline antibiotic that targets DNA by intercalating into the double helix, forming stable complexes with calf thymus DNA. Its primary activity includes the inhibition of prokaryotic nucleic acid polymerases, such as E. coli DNA polymerase I and RNA polymerase. This compound is particularly useful in cancer research and investigations into bacterial infections, providing insights into therapeutic mechanisms and potential treatment strategies. -
Antibacterial Agent
S-MGB-234 is an antibacterial agent that functions as a minor groove binder, specifically targeting the causative agents of Animal African Trypanosomiasis (AAT). This compound demonstrates potent in vitro activity against Trypanosoma congolense and Trypanosoma vivax, the primary pathogens responsible for AAT. Notably, S-MGB-234 exhibits a unique resistance profile, lacking cross-resistance with existing diamidine agents and not utilizing the transporters commonly associated with diamidines. -
RdRP Inhibitor
RdRP-IN-3 is an inhibitor of RNA-dependent RNA polymerase (RdRp), providing a potent approach for antiviral research against influenza viruses. This compound effectively disrupts RdRp activity, thereby hindering viral replication and proliferation. It serves as a valuable tool in studying the mechanisms of influenza pathogenesis and evaluating potential antiviral therapies. -
Antibacterial Agent
Lavofloxacin lactate is an antibacterial agent that primarily targets DNA gyrase and topoisomerase IV, leading to the inhibition of DNA replication and repair in bacteria. This broad-spectrum antimicrobial compound exhibits potent bactericidal activity against a wide range of bacterial species. Researchers can utilize Lavofloxacin lactate to investigate bacterial resistance mechanisms, including the analysis of resistance genes and mutations. -
Antibiotic
Erythromycin A dihydrate is a macrolide antibiotic that targets the bacterial 50S ribosomal subunit, effectively inhibiting RNA-dependent protein synthesis through the blockage of transpeptidation and translocation reactions. It possesses a broad spectrum of antimicrobial activity and is commonly used in microbiological research. Additionally, Erythromycin A dihydrate has demonstrated antitumor and neuroprotective effects, making it valuable for diverse applications in biological research. -
Antibiotic
Erythromycin stearate is a macrolide antibiotic that targets bacterial 50S ribosomal subunits, leading to the inhibition of RNA-dependent protein synthesis through the blockage of transpeptidation and translocation reactions. It exhibits a broad spectrum of antimicrobial activity against various gram-positive and some gram-negative bacteria. In addition to its antibacterial properties, erythromycin stearate has been investigated for its potential antitumor and neuroprotective effects, making it suitable for diverse research applications in microbiology and cancer studies. -
DENV NS5 RdRp Inhibitor
3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is a nucleotide analog that serves as a potent inhibitor of DENV NS5 RNA-dependent RNA polymerase (RdRp). Functioning as a chain terminator, it effectively suppresses RNA synthesis, making it a valuable tool in virology research. With an IC50 of 0.02 μM against DENV NS5 RdRp, this compound is crucial for studies focusing on antiviral mechanisms and the development of therapeutic strategies targeting dengue virus infections. -
HBV Inhibitor
HBV-IN-53 is an inhibitor of Hepatitis B virus (HBV) that effectively reduces serum levels of HBV DNA. Its potent antiviral activity makes it a valuable tool for research in HBV therapeutics. Additionally, HBV-IN-53 has been shown to exhibit an additive inhibitory effect when combined with Tenofovir disoproxil fumarate, highlighting its potential for use in combination therapy studies. -
HIV-1 Inhibitor
SJP-L-5 is an HIV-1 capsid dissociation inhibitor that targets the HIV-1 viral capsid, preventing its normal function. It demonstrates significant inhibitory activity against various HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. By effectively blocking the entry of HIV-1 viral DNA into the nucleus, SJP-L-5 offers valuable potential for applications in HIV-1 infection research and development of antiviral therapies. -
Antibacterial Agent
A-65282 is an antibacterial agent that inhibits P4 DNA unknotting, exhibiting an IC50 value of 8 µg/mL. This compound induces DNA breakage through the action of calf thymus topoisomerase II, making it a valuable tool for studying DNA replication and repair mechanisms. Its targeted enzymatic disruption highlights its potential in antibacterial research contexts. -
Antibiotic
Eponemycin is an antibiotic with significant antitumor properties, targeting cancer cell proliferation. It demonstrates potent cytotoxicity against various cancer cell lines including B16-F10, L1210, P388, and HCT-116, with IC50 values of 0.0017, 0.01, 0.031, and 0.0097 µg/mL, respectively. Additionally, Eponemycin effectively inhibits DNA synthesis in the B16-F10 cell line, exhibiting an IC50 of 0.1 µg/mL, thereby demonstrating its utility in cancer research applications focused on DNA replication and cell viability. -
Antibacterial Agent
Anti-MRSA agent 28 is an antibacterial agent specifically designed to target multidrug-resistant (MDR) gram-positive bacterial strains. With minimum inhibitory concentrations (MICs) ranging from 0.06 to 0.125 μg/mL, it effectively inhibits bacterial growth by targeting DNA polymerase IIIC, demonstrating an IC50 of 3.80 μg/mL. This compound exhibits strong antibacterial activity and has anti-inflammatory properties, making it a valuable tool for research applications related to the treatment of gram-positive infections. -
Antiviral Agent
Antiviral agent 67 (compound PC6) is a potent inhibitor of the dengue virus (DENV) NS5 RNA-dependent RNA polymerase, exhibiting a Ki value of 1.12 nM. It demonstrates significant antiviral activity, making it a valuable tool for research focused on DENV replication and antiviral drug discovery. This compound is suitable for studies aimed at understanding the mechanisms of antiviral action and evaluating potential therapeutic strategies against dengue virus infections. -
Antitumor Antibiotic
2-Hydroxyaclacinomycin A is an anthracycline antibiotic that exerts its antitumor effects through the inhibition of RNA and DNA synthesis. It demonstrates potent cytotoxic activity against leukemia L-1210 cells, with IC50 values of 0.10 μg/mL and 0.95 μg/mL for RNA and DNA synthesis, respectively. This compound is valuable for research focused on cancer therapeutics and the cellular mechanisms of anthracycline antibiotics. -
Antitumor Antibiotic
1-Hydroxyoxaunomycin is an antitumor antibiotic that targets cellular proliferation. It effectively inhibits U210 cell growth, demonstrating IC50 values of 0.0005 μg/mL for cell growth, 1.00 μg/mL for DNA synthesis, and 0.76 μg/mL for RNA synthesis. This compound is primarily utilized in cancer research to explore mechanisms of action related to nucleic acid synthesis and cellular function. -
Antibacterial Agent
DV-7751A is a fluoroquinolone antibiotic that primarily inhibits the supercoiling activity of DNA gyrases. This compound demonstrates significant antimicrobial activity against a range of bacterial strains, including Streptococcus pneumoniae, Streptococcus pyogenes, and Peptostreptococcus species. Additionally, DV-7751A exhibits a rapid bactericidal effect against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, making it a valuable reagent for research in antibacterial therapeutics.
